Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Published online December 5, 2005.
Copyright & Usage
THE JOURNAL OF NUCLEAR MEDICINE
Author Information
- Andreas H. Jacobs, MD1,2,3,
- Anne Thomas, MD1,2,
- Lutz W. Kracht, MD1,
- Huongfeng Li, PhD1,
- Claus Dittmar, PhD1,
- Guido Garlip, MD1,
- Norbert Galldiks, MD1,
- Johannes C. Klein, MD1,
- Jan Sobesky, MD1,2,
- Rüdiger Hilker, MD1,2,
- Stefan Vollmar, PhD1,2,
- Karl Herholz, MD1,2,
- Klaus Wienhard, PhD1 and
- Wolf-Dieter Heiss, MD1,2,3
Statistics from Altmetric.com
Cited By...
Article usage
In this issue
Jump to section
Related Articles
Cited By...
- Simultaneous Mapping of Vasculature, Hypoxia, and Proliferation Using Dynamic Susceptibility Contrast MRI, 18F-FMISO PET, and 18F-FLT PET in Relation to Contrast Enhancement in Newly Diagnosed Glioblastoma
- Head-to-Head Comparison of 11C-PBR28 and 18F-GE180 for Quantification of the Translocator Protein in the Human Brain
- Repeatability of 18F-FLT PET in a Multicenter Study of Patients with High-Grade Glioma
- The Role of PET [18F]FDOPA in Evaluating Low-grade Glioma
- PET Findings of Intramedullary Tumors of the Spinal Cord Using [18F] FDG and [11C] Methionine
- Correlation of MRI-Derived Apparent Diffusion Coefficients in Newly Diagnosed Gliomas with [18F]-Fluoro-L-Dopa PET: What Are We Really Measuring with Minimum ADC?
- Correlation of 18F-FLT Uptake with Tumor Grade and Ki-67 Immunohistochemistry in Patients with Newly Diagnosed and Recurrent Gliomas
- Analysis of the Growth Dynamics of Angiogenesis-Dependent and -Independent Experimental Glioblastomas by Multimodal Small-Animal PET and MRI
- 3'-Deoxy-3'-18F-Fluorothymidine PET and MRI for Early Survival Predictions in Patients with Recurrent Malignant Glioma Treated with Bevacizumab
- Concurrent Temozolomide and Dose-Escalated Intensity-Modulated Radiation Therapy in Newly Diagnosed Glioblastoma
- Specific biomarkers of receptors, pathways of inhibition and targeted therapies: clinical applications
- Imaging biomarkers of brain tumour margin and tumour invasion
- Discriminant Analysis of 18F-Fluorothymidine Kinetic Parameters to Predict Survival in Patients with Recurrent High-Grade Glioma
- Multimodality Assessment of Brain Tumors and Tumor Recurrence
- Tumor 3'-Deoxy-3'-18F-Fluorothymidine (18F-FLT) Uptake by PET Correlates with Thymidine Kinase 1 Expression: Static and Kinetic Analysis of 18F-FLT PET Studies in Lung Tumors
- Correlation of 6-18F-Fluoro-L-Dopa PET Uptake with Proliferation and Tumor Grade in Newly Diagnosed and Recurrent Gliomas
- Kinetics of 3'-Deoxy-3'-18F-Fluorothymidine During Treatment Monitoring of Recurrent High-Grade Glioma
- Switching on the Lights for Real-Time Multimodality Tumor Neuroimaging: The Integrated Positron-Emission Tomography/MR Imaging System
- Kinetic Modeling of 3'-Deoxy-3'-18F-Fluorothymidine for Quantitative Cell Proliferation Imaging in Subcutaneous Tumor Models in Mice
- First Demonstration of Leukemia Imaging with the Proliferation Marker 18F-Fluorodeoxythymidine
- Imaging of Cell Proliferation: Status and Prospects
- Glioma Proliferation as Assessed by 3'-Fluoro-3'-Deoxy-L-Thymidine Positron Emission Tomography in Patients with Newly Diagnosed High-Grade Glioma
- Dynamic Small-Animal PET Imaging of Tumor Proliferation with 3'-Deoxy-3'-18F-Fluorothymidine in a Genetically Engineered Mouse Model of High-Grade Gliomas
- Predicting Treatment Response of Malignant Gliomas to Bevacizumab and Irinotecan by Imaging Proliferation With [18F] Fluorothymidine Positron Emission Tomography: A Pilot Study
- Clinical Applications of PET in Brain Tumors
- Imaging-Guided Gene Therapy of Experimental Gliomas
- Kinetic Analysis of 3'-Deoxy-3'-18F-Fluorothymidine in Patients with Gliomas